The French drugmaker has joined the likes of Moderna, BioNTech and CureVac in advancing an mRNA vaccine against the virus that causes COVID-19 that could take the fraction of the time to develop compared with the old egg- and cell-based technology.
Sanofi has begun a second coronavirus vaccine project, linking up with Translate Bio Inc. of the US to develop a messenger RNA (mRNA) vaccine that should be quicker and cheaper than the traditional approach.
The two companies, which have been partners since 2018 when they signed a deal to develop mRNA vaccines for up to five infectious diseases, will investigate multiple candidates to advance a vaccine for SARS-CoV-2
Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.
A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.
Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.
Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.
The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.
